74
Participants
Start Date
May 24, 2011
Primary Completion Date
March 13, 2017
Study Completion Date
March 13, 2017
Vinorelbine 25 mg/m2 weekly
Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
Afatinib 40mg once daily (OD)
Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
Paclitaxel 80 mg/m2 weekly
Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
National Taiwan University Hospital, Taipei
Koo Foundation Sun Yet-Sen Cancer Center, Taipei
Taipe Veterans General Hospital, Taipei
China Medical University Hospital, Taichung
Mackay Memorial Hospital, Taipei
Taichung Veterans General Hospital, Taichung
N.A. Semashko Central Clinical Hospital, Moscow, Moscow
Clinical Oncology Dispensary No. 1, Dept. Chemotherapy, Krasnodar
"GUZ Oncological Dispesary #2", Sochi
"SBIH of Stavropol territory Pyatigorsk Oncol. Dispensary", Pyatigorsk
Ruby Hall Clinic, Pune
"St.Auton.Heal.Inst.Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan", Kazan'
Central India Cancer Research Institute, Nagpur
Sujan Surgical Cancer Hospital, Amravati
Queen Mary Hospital, Hong Kong
Prince of Wales Hospital, Shatin
Tata Memorial Hospital, Maharashtra
Curie Manavata Cancer Centre, Maharashtra
Regional Cancer Center, Thiruvananthapuram
University Clinical Center, Gdansk, Gdansk
"SBIH Samara Regional Clinical Oncol. Dispensary, Samara", Samara
Stavropol Regional Clin. Oncology Dispensary Dept. Oncology, Stavropol
Yaroslavl Regional Clinical Oncology Hosp. Dept.Chemotherapy, Yaroslavl
North Devon District Hospital, Barnstaple
Royal Bournemouth and Christchurch Hospital, Bournemouth
Royal Devon and Exeter Hospital, Exeter
Charing Cross Hospital, London
Lead Sponsor
Boehringer Ingelheim
INDUSTRY